INVO Bioscience (INVO) Stock Price, News & Analysis

Company Overview

INVO Bioscience, Inc. is a medical technology company focused on advancing fertility treatments through innovative intravaginal culture solutions. The company’s flagship product, INVOcell®, is a proprietary device designed to facilitate in vitro fertilization (IVF) by allowing fertilization and early embryo development to occur within a patient’s vaginal cavity. By integrating key steps of the IVF process into a single device, INVOcell® aims to simplify laboratory requirements, potentially reduce procedural costs, and offer a patient-centric approach to assisted reproductive technology.

INVO Bioscience’s primary business activities encompass product development, regulatory approval, and commercialization of its INVOcell® system. The company collaborates with fertility clinics and healthcare providers to integrate its intravaginal culture solution into existing IVF protocols. In addition to device manufacturing, INVO Bioscience provides specialized training and support services, ensuring clinicians are fully equipped to adopt and optimize intravaginal culture procedures in their practices.

Since its founding in 2007, INVO Bioscience has pursued a strategy of global expansion through strategic partnerships and licensing agreements. Headquartered in Beverly, Massachusetts, the company has extended its reach into North America, Latin America, Europe, Asia and the Middle East. These collaborations enable local fertility centers to offer INVOcell® as an alternative to conventional laboratory-based IVF, broadening access to fertility care in diverse healthcare markets.

The company’s leadership team combines deep expertise in reproductive medicine, regulatory affairs and commercial operations. Founder and Chairman Dr. Jerome F. Sher, a pioneer in minimally invasive reproductive technologies, guides INVO Bioscience’s scientific vision. President and CEO Javier Suarez oversees global strategy, business development and operational execution. Under this management structure, INVO Bioscience continues to advance research, secure regulatory clearances and strengthen its position as a leader in patient-focused fertility solutions.

Key Stats

• Today's Range: $0.77 to $0.82
• 50-Day Range: $0.78 to $2.18
• 52-Week Range: $0.63 to $3.50
• Volume: 84,593 shs
• Average Volume: 1.59 million shs
• Market Capitalization: $3.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

INVO Stock Analysis - Frequently Asked Questions

How have INVO shares performed this year?

INVO Bioscience's stock was trading at $0.81 on January 1st, 2025. Since then, INVO stock has increased by 1.2% and is now trading at $0.8199.

How were INVO Bioscience's earnings last quarter?

INVO Bioscience, Inc. (NASDAQ:INVO) announced its quarterly earnings data on Monday, November, 15th. The company reported ($4.80) earnings per share for the quarter, missing the consensus estimate of ($4.00) by $0.80. The business earned $0.22 million during the quarter, compared to analyst estimates of $0.25 million.

When did INVO Bioscience's stock split?

INVO Bioscience shares reverse split before market open on Thursday, July 27th 2023.The 1-20 reverse split was announced on Thursday, July 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of INVO Bioscience?

Shares of INVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of INVO Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that INVO Bioscience investors own include NVIDIA (NVDA), NIO (NIO), Tesla (TSLA), Meta Platforms (META), Broadcom (AVGO) and Bilibili (BILI).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 7/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: N/A
• Current Symbol: NASDAQ:INVO
• CIK: 1417926
• Web: www.invobioscience.com
• Phone: (978) 878-9505
• Fax: N/A
• Employees: 25
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.03 million
• Net Margins: -122.79%
• Pretax Margin: -122.32%
• Return on Equity: N/A
• Return on Assets: -36.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.30
• Quick Ratio: 0.27

Sales & Book Value

• Annual Sales: $5.77 million
• Price / Sales: 0.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.06) per share
• Price / Book: -0.39

Miscellaneous

• Outstanding Shares: 3,809,000
• Free Float: 3,769,000
• Market Cap: $3.05 million
• Optionable: No Data
• Beta: 1.43